- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2020
- EULAR 2019
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2019
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2019
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- SlideSet RA
- FOCUS «Der Fuss»
- FOCUS «Die Hand»
- FOCUS «Kinderrheuma»
ACR Boston 2014 | Daily Highlights
A Multicenter, Prospective Cohort Study Using Nailfold Videocapillaroscopy and Other Clinical Characteristics to Determine the Risk of Developing New Digital Ulcers in Patients with Systemic SclerosisAbstract: 1928
Presenter: Vanessa Smith
Co-Authors: Maurizio Cutolo, Ariane Herrick, Oliver Distler, Mike Becker, Emma Beltran, Patrick Carpentier, Clodoveo Ferri, Murat Inanc, Panayiotis Vlachoyiannopoulos, Harbajan Chadha-Boreham, Emmanuelle Cottreel, Thomas Pfister, Daniel Rosenberg and Juan Torres, on behalf of the CAP study investigators
Digital ulcers (DU) are painful and disabling and affect almost 50% of systemic sclerosis (SSc) patients. Nailfold videocapillaroscopy (NVC) non-invasively assesses SSc-related micro-angiopathy and may be useful in predicting clinical progression of digital vasculopathy, especially DU.1-4The objective of this study was to identify NVC variables and clinical characteristics which predict the occurrence of new DU in SSc patients.
The aim of this study was to examine the standardized mortality ratios (SMR) for all-cause and cause-specific deaths in SLE patients followed prospectively at a large lupus clinic between 1970 and 2012.
International, prospective, multicenter cohort study in SSc. Eligibility was not restricted by medication use. SSc patients (American College of Rheumatology/LeRoy and Medsger) were enrolled in two strata: 'DU History' and 'No DU History'. The No DU History patients had early disease (≤2 years).
Variables were classified into bundles for statistical analysis: demographics, SSc clinical characteristics, DU characteristics, NVC characteristics and other clinical characteristics. NVC variables for fingers II–V were evaluated locally in a standardized way. Patients were followed up to 6 months for new DUs (confirmed by the investigator). Univariable Logistic Regression (ULR) was performed on all variables and Multivariable Logistic Regression (MLR) was performed within and across bundles to assess statistical significance (Wald chi-square p<0.15 for linear and p<0.05 for quadratic) and discriminatory ability (receiver operation characteristic area under the curve [ROC AUC]). Clinical relevance to predict new DU in 6 months was portrayed by model performance characteristics in a binary risk chart and two-by-two tables at different risk probability thresholds.
SMRs were modelled using Poisson regression with the log of the expected number of events as an offset, and adjusted for age, sex, disease duration and decade of death.
Of the 623 patients enrolled in 59 centers, 591 had data on DU outcome (new DU or no new DU) during the study. 468 (79%) patients had a DU history, of whom 103 (22%) developed new DU. 123 (21%) patients had no DU history, of whom 5 (4%) developed new DU. Due to low event numbers in the no DU history group, the present analysis focuses on the DU history stratum. The mean age was 54.0 years, 79.5% were females, and 59.8% patients had limited cutaneous SSc. The final model consisted of the following 3 co-variables to predict the occurrence of DU within 6 months: number of DU at baseline visit categorized into 0, 1, 2 and ≥ 3, mean number of capillaries in the middle finger of the dominant hand (evaluated on two adjacent fields in the middle of the nailfold) and presence/absence of critical digital ischemia at enrolment. AUC of this model was 0.738 (C.I. 0.681-0.795). Internal validation through bootstrap generated AUC 0.633 [C.I. 0.510-0.756]). At a probability threshold of 37.3%, the binary risk table shows a specificity of 90.6%, a sensitivity of 39.4%, a negative predictive value (NPV) of 83.8% and a positive predictive value (PPV) of 54.9%.
The CAP study is the first and largest prospective study producing a simple prognostic model with acceptable performance which can be useful in the management of patients with presence or history of DU.
1. Cutolo M et al. Nature Rev Rheumatol 2010;6:578–87;
2. Smith V et al. Ann Rheum Dis 2011;70:180–3;
3. Sebastiani M et al. Ann Rheum Dis 2012;71:67–70;
4. Smith V et al. Ann Rheum Dis 2012;71:1636-9
Disclosure of Interest:
V. Smith, Actelion Pharmaceuticals Ltd, 2; M. Cutolo, Actelion Pharmaceuticals Ltd, 2; A. Herrick, Actelion Pharmaceuticals US, 5, Pfizer Inc, 5; O. Distler, Actelion Pharmaceuticals US, 5, Pfizer Inc, 5, Ergonex, 5, Bristol-Myers Squibb, 5, Bayer, 5, United BioSource Corporation, 5, Roche/Genentech, 5, Medac, 5, Biovitrium, 5, Boehringer Ingelheim Pharma, 5, Novartis Pharmaceutical Corporation, 5, 4D Science, 5, Active Biotec, 5, Sinoxa, 5, Sanofi-Aventis Pharmaceutical, 5, Serodapharma, 5, GSK, 5, Epipharm, 5; M. Becker, None; E. Beltran, None; P. Carpentier, None; C. Ferri, None; M. Inanc, Actelion Pharmaceuticals US, 5; P. Vlachoyiannopoulos, None; H. Chadha-Boreham, Actelion Pharmaceuticals US, 3; E. Cottreel, Actelion Pharmaceuticals US, 3; T. Pfister, Actelion Pharmaceuticals US, 3; D. Rosenberg, Actelion Pharmaceuticals US, 3; J. Torres, on behalf of the CAP study investigators, Actelion Pharmaceuticals US, 3.
Nailfold capillaroscopy was in the past most often used for the early detection of systemic sclerosis, U1-RNP- positive mixed connective tissue disease and dermatomyositis. This study has direct clinical impact as it highlights the potential of nailfold capillaroscopy not only for the early diagnosis of SSc patients, but also for the use as a prognostic tool to determine the risk of digital ulcers in SSc. Strengths of the study are the large number of patients, the prospective and multicenter study design, and the advanced statistical analyses including validation methods. As a limitation, it has to be noted that the presence of digital ulcers at baseline was by itself the strongest predictor of later ulcer development. Thus, despite the useful and independently significant support that one can get form nailfold capillaroscopy, clinical examination remains the mainstay in risk assessment for digital ulcers in SSc patients.
Prof. Dr. med. Oliver Distler
> zurück zur Übersicht